This meeting will explore the emerging field of immunometabolism, examining how metabolic and immune processes interact across biological scales in health and disease. Topics will include nutrient signaling, microbial metabolites, neuro-immune interactions, and the role of these mechanisms in aging and age-related diseases. By uniting experts from metabolism and immunology, the program will foster collaborations, tool-sharing, and innovative research directions. Attendees will gain fresh perspectives and practical approaches to advance their own work.

This meeting will showcase state-of-the-art advances and chart future directions in cell therapy. Sessions will address which diseases are best suited for cellular interventions, what programmable functions are needed to achieve success, and how clinical trials can inform basic research and innovation. By convening synthetic biologists, cell engineers, clinicians, and industry leaders, the program will foster cross-disciplinary dialogue, catalyze new collaborations, accelerate clinical impacts and help define the next generation of cell therapies.

Make plans to join us again in Los Angeles for AACR IO 2026—encompassing the very best of basic, translational, and clinical research in immunology, inflammation, and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies. The inaugural AACR IO 2025 program attracted over 600 basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. The comprehensive and unique format included a mix of keynote lectures, major symposia, spotlight sessions, educational sessions, special sessions, and poster sessions with exhibits.

The Immunoengineering GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes an array of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, and afternoon free time and communal meals allow for informal networking opportunities with leaders in the field.

The 10th Immuno-Oncology Symposium will bring together researchers and clinicians to discuss innovations shaping the future of immuno-oncology. Topics include treatment concepts such as immune engagers, cellular therapies, immune checkpoint inhibition and cutting-edge basic science approaches to understand mechanisms of action, resistance and side effects of cancer immunotherapies.

The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

This meeting will bring together a diverse group of basic, translational and clinical researchers including those from academia, industry and government to cooperatively discuss the mechanistic basis of failed immunotherapy, and novel approaches to activating the immune system, in order to provide insight for future clinical applications of novel approaches and optimal combination therapies.

The 2026 SITC Spring Scientific will bring together experts in cell therapy, drug development, and immuno-oncology to address the timely topic of next-generation cellular therapies, T cell engagers, and combination therapies to treat cancer.

The highlight of the Summit4CI is an annual conference that brings together up to 350 leading scientists, clinicians, students and economists with representatives from industry, patient groups, charities and government. The conference explores the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives, through internationally recognized speakers, scientific presentations, poster sessions, panel discussions an Oxford-style debate and networking opportunities.

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest not-for-profit annual meeting in Europe focused on cancer immunotherapy research and development, CIMT invites international participants for high-level scientific exchange, collaboration, and education.

This Keystone Symposia Conference will explore interactions between tumor cells and their surrounding microenvironment, examining both tumor-intrinsic and -extrinsic signaling programs that influence cancer progression and systemic host responses such as aging, cachexia, obesity, and immunity. The program will highlight innovative experimental and computational tools to study the tumor microenvironment (TME), with a focus on identifying tumor vulnerabilities, new therapeutic targets, and methods for patient stratification. A hands-on “data jamboree” workshop will showcase analytical tools developed by the NCI Human Tumor Atlas Network (HTAN) to analyze the TME.

This meeting will bring together experts in cancer biology, immunology, computational biology, chemical biology, and beyond, to catalyze cross-disciplinary collaborations and insights with clinical impacts.

This Aegean conference on cytokine signaling in cancer aims to bring together outstanding experts in fundamental and translational cytokine research to foster collaboration and knowledge in understanding cancer etiology, pathogenesis, and response to immunotherapies, along with devising novel cytokine-specific diagnostic approaches and treatment modalities.

St Jude Children’s Research Hospital and Technical University of Munich are proud to host the ‘ImmunoMemphis’ symposium where the immunological community will come together in Memphis, Tennessee to discuss fundamental mechanisms of T cell differentiation, and how these insights can be translated into durable immunotherapies for cancer and chronic viral infections.

Topics will include conceptual and technical advances that are reshaping our understanding of T cell immunological memory, current barriers in establishing T cells with tissue/tumor-homing properties, resistance to local-immunosuppression, and the capacity for establishing disease control with long-term immunological protection.

Details TBD

TBD

This year’s program will continue that tradition of innovation by examining the structural and functional dynamics of immunoreceptors, their mechanisms of activation and regulation, and translational research driving new immunotherapeutic strategies. As key molecules that regulate immune responses, research into immunoreceptors has yielded precise and effective therapies, including checkpoint inhibitors, CAR-T cell therapies, and novel monoclonal antibodies.

TBD

Cochairs

Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, New York
Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California